Table 1:
Population-based registries evaluating the incidence of secondary primary malignancies in multiple myeloma
| Author | Registry | Study period | Patients (n) | All SPM n (%) | Hematologic SPM n (%) | Solid tumor SPM n (%) | All SPM SIR (95% CI) | Hematologic SPM SIR (95% CI) | Solid tumor SPM SIR (95% CI) | Latency (median) |
|---|---|---|---|---|---|---|---|---|---|---|
| Dong et al. [5] | Swedish Cancer Registry | 1958-1996 | 8656 | 475 (5.5) | 83 (1.0) | 392 (4.5) | NR | All 2.19 (1.74-2.71); AML 8.19 (5.70-11.4); NHL 1.74 (1.12-2.57) | All 0.81 (0.70-0.90) | 2.9 years |
| Mailankody et al. [6] | Swedish Cancer Registry | 1986-2005 | 8740 | 577 (6.6) | 69 (0.8) | 508 (5.8) | 1.26 (1.16-1.36) | All 2.04 (1.59-2.58); AML/MDS 11.51 (8.19-15.74) | All 1.19 (1.09-1.30); GI 1.30 (1.09-1.53); nonmelanoma skin 2.22 (1.74-2.80) | 45.3 months (MDS/AML) |
| Youlden et al. [7] | Queensland Cancer Registry | 1982-2001 | 2174 | 134 (0.6) | NR | NR | Males 1.04 (0.84-1.27); Females 0.89 (0.64-1.21) | NR | NR | NR |
| Chakraborty et al. [8] | SEER | 1973-2008 | 3245 | 1657 (51.1) | 214 (6.6) | 1394 (43.0) | 0.99 (0.95-1.04) | All 1.68 (1.46-1.92); Leukemia 3.07 (2.57-3.64) | All 0.94 (0.89-0.99); Invasive skin 1.43 (1.09-1.85) | NR |
| Razavi et al. [10] | SEER | 1973-2008 | 36,491 | 2012 (5.5) | 263 (0.7) | 1707 (4.7) | 0.98 (0.94-1.02) | All 1.63 (1.45-1.84); leukemia 2.94 (2.52-3.43); AML 6.51 (5.42-7.83); NHL 1.28 (1.04-1.57); CLL 0.34 (0.17-0.68) | All 0.92 (0.88-0.97); esophagus 0.49 (0.28-0.87); lung/bronchus 0.88 (0.78-0.99); breast 0.81 (0.69-0.94); melanoma 1.36 (1.07-1.74); bladder 1.22 (1.03-1.44); kidney 1.30 (1.01-1.66); thyroid 1.63 (1.05-2.52) | 5.2 years |
| Tzeng et al. [9] | National Health Research Institutes (Taiwan) | 1997-2009 | 3970 | 71 (1.8) | 35 (0.9) | 36 (0.9) | NR | All 13.0 (7.79-21.6); AML 23.9 (10.5-54.5); NHL 7.72 (3.83-15.6) | All 0.57 (0.40-0.79) | 1.9 years |
| Ailawadhi et al. [11] | SEER | 1973-2008 | NR | 2021 | NR | NR | Hispanic Whites 0.67 (0.50-0.88); non-Hispanic whites 0.97 (0.92-1.02); African American 1.07 (0.97-1.18); Asians/Pacific Islanders 1.11 (0.87-1.40) | AML: Hispanic Whites 1.54 (0.04-8.58); non-Hispanic Whites 6.85 (5.55-8.38); African Americans 6.24 (3.41-10.47); Asians/Pacific Islanders 6.32 (1.72-16.19) | All: Hispanic Whites 0.66 (0.48-0.89); non-Hispanic Whites: 0.90 (0.85-0.95); African Americans 1.05 (0.94-1.17); Asians/Pacific Islanders 1.03 (0.79-1.33) | 4.7 years |
NR-not reported, SPM-secondary primary malignancies, SIR-standardized incidence ratio, CI-confidence interval, SEER-Surveillance Epidemiology and End Results